Teeple, A. and Muser, E. 2018. Cost per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 2, (Dec. 2018), S80. DOI:https://doi.org/10.25251/skin.2.supp.81.